Skip to main content

Table 2 Clinicopathological features of 149 patients who were treated with preoperative chemotherapy

From: Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer

Parameters (n = 149)

Number of patients (%)

Age (years old)

56 (24–75)

Tumour size (mm)

27.6 (10.2–98.0)

Skin infiltration

 Negative/positive

134 (89.9%)/15 (10.1%)

Lymph node metastasis

 N0/N1/N2/N3

51 (34.2%)/54 (36.2%)/29 (19.5%)/15 (10.1%)

HER2

 Negative/positive

87 (58.4%)/62 (41.6%)

Ki67

 Negative/positive

23 (15.4%)/126 (84.6%)

ORR

 Non-responders/responders

11 (7.4%)/138 (92.6%)

pCR

 Negative/positive

75 (50.3%)/74 (49.7%)

Recurrence

 Negative/positive

123 (82.6%)/26 (17.4%)

TILs

 Low/high

58 (38.9%)/91 (61.1%)

Smoker

 No/yes

105 (70.5%)/44 (29.5%)

Pack-years of smokers

20 (2.5–135)

Pack-years

 Low/high

106 (71.1%)/43 (28.9%)

  1. HER human epidermal growth factor receptor, ORR objective response rate, pCR pathological complete response, TILs tumour-infiltrating lymphocytes